

Difference in CD4/CD8 ratio in patients switched from triple therapy (TT) to mono/dual therapy

Mean change CD8 (cells/ μ L)	Triple Therapy	Mono/Dual Therapy	P-value
12 months (IQR)	- 40 (343)	+ 38 (286)	0.010
24 months (IQR)	- 50 (294)	+ 78 (303)	<0.001
Mean change CD4/CD8 ratio (log10), (IQR)	Triple Therapy	Mono/Dual Therapy	P-value
12 months (IQR)	+ 0.06 (0.07)	+ 0.05 (0.13)	0.051
24 months (IQR)	+ 0.12 (0.21)	+ 0.04 (0.10)	0.002

Despite the limitations of a cohort study, this shows that a less drug regimen could have an impact on the immune system, decreasing CD4/CD8 ratio by increasing CD8